Q-omics provides the consensus-scored RDM1P3 profile across patient tissues and cancer cell-line models. RDM1P3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RDM1P3 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, RDM1P3 RNA expression shows 17,531 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, BRCA, and THYM as cancer lineages where RDM1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RDM1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RDM1P3 survival associations across molecular data types. RDM1P3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RDM1P3 RNA expression–survival associations across cancer types. High RDM1P3 expression shows unfavorable associations in LUSC and COAD, but favorable associations in SKCM, LAML, UCS and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for RDM1P3 RNA expression.
This table summarizes RDM1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RDM1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RDM1P3 shows lower tumor expression in BRCA and UCEC and higher tumor expression in LIHC, CHOL, KIRC and PAAD. The BRCA box plot shows higher RDM1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.557, t-test p < 0.001).
This table shows molecular features associated with RDM1P3 in patient tissues and cancer cell lines. In patient samples, RDM1P3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
